The US Centers for Medicare and Medicaid Services did not describe how it arrived at Medicare negotiated prices for the first 10 Part D drugs to go through the process in its 15 August announcement, which likely means that at least some manufacturers in the second round will not have the benefit of experience to help navigate the process.
Key Takeaways
-
Stakeholders hoping to learn from the initial round of Medicare price negotiations may have to wait until March for insight into the agency’s approach because the price announcement was not very informative.
CMS will announce the next group of drugs targeted for negotiation on 1 February 2025, but it is not required...
